Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139 · Astellas Pharma Global Development, Inc. · PHASE1 · terminated · last registry update 2026-09-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.” | – | Registry record, Astellas Pharma Global Development, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NECTIN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-11Phase 3 first posted: Summit Therapeutics, Ivonescimab Dose 1 + enfortumab vedotin (EV) (NCT07815665)
- 2026-08-04Results posted on the registry: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-22Phase 3 first posted: AstraZeneca, Dato-DXd + Rilvegostomig (NCT07720284)
- 2026-06-30Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Enfortumab Vedotin (NCT03924895)
- 2026-05-04Phase 3 first posted: Astellas Pharma Global Development, Inc., Enfortumab vedotin + Cisplatin (NCT07566156)
- 2026-04-13Results posted on the registry: Astellas Pharma Global Development, Inc., enfortumab vedotin + pembrolizumab (NCT04225117)
- 2026-03-24Also stopped (terminated): Astellas Pharma Global Development, Inc., enfortumab vedotin (EV) + pembrolizumab (NCT03288545)
- 2026-01-16Phase 3 first posted: Guliz Ozgun, enfortumab vedotin and pembrolizumab (EV/P) (NCT07346053)
- 2025-10-20Phase 3 first posted: Eli Lilly and Company, Vepugratinib + EV (NCT07218380)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision